NCT03233711 2026-04-13
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Institut du Cancer de Montpellier - Val d'Aurelle
AIDS Malignancy Consortium
Eastern Cooperative Oncology Group